INT60337

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.46
First Reported 1993
Last Reported 2010
Negated 0
Speculated 1
Reported most in Body
Documents 8
Total Number 12
Disease Relevance 4.69
Pain Relevance 1.83

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (THBS1) extracellular region (THBS1) cell adhesion (THBS1)
structural molecule activity (THBS1)
Anatomy Link Frequency
endothelial cell 1
erythrocyte 1
fundus 1
THBS1 (Homo sapiens)
Pain Link Frequency Relevance Heat
endometriosis 42 99.16 Very High Very High Very High
Dismenorea 14 98.60 Very High Very High Very High
pain pelvic 30 96.76 Very High Very High Very High
Inflammation 83 88.32 High High
COX-2 inhibitor 4 83.40 Quite High
agonist 4 80.60 Quite High
corticosteroid 1 69.20 Quite High
dexamethasone 25 63.76 Quite High
Pain 6 51.88 Quite High
palliative 7 50.00 Quite Low
Disease Link Frequency Relevance Heat
Endometriosis 64 99.16 Very High Very High Very High
Disease 31 98.68 Very High Very High Very High
Reprotox - General 3 32 96.76 Very High Very High Very High
Apoptosis 25 95.44 Very High Very High Very High
Wound Healing 19 94.56 High High
Cancer 304 92.56 High High
Repression 7 92.24 High High
INFLAMMATION 86 88.32 High High
Diabetes Mellitus 2 77.04 Quite High
Endometriosis (extended) 3 75.52 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Flag empty vector or different dose of Flag-tagged E2F-1 expression vector, TSP1(?
Positive_regulation (tagged) of TSP1
1) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.09 Pain Relevance 0
In addition, in order to test whether pRB1 could affect the transactivation of E2F-1 on TSP1 promoter, we transfected two different dosage of HA-tagged pRB1 (0.2µg and 0.5µg/per well in 24-well plates) together with HA-tagged E2F-1(0.2 µg/per well in 24-well plates) and performed promoter assays, pRB1 could indeed suppress the transactivity of E2F-1 on TSP1 promoter in a dose-dependent manner (Fig. 2H), which is consistent with the effect of pRB1 on other bona fide targets of E2F-1.
Positive_regulation (transactivation) of TSP1
2) Confidence 0.46 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
These data suggest that activated platelet release factors, including alpha-granule TSP, which promote receptor-mediated sickle erythrocyte adherence to microvascular endothelium.
Positive_regulation (activated) of TSP in erythrocyte
3) Confidence 0.44 Published 1993 Journal Blood Section Abstract Doc Link 8471771 Disease Relevance 0.07 Pain Relevance 0
These results not only further confirmed the up-regulation of TSP-1 by E2F-1 effectively, but also ruled out the non-specific up-regulation of TSP-1 promoter activity as a result of ectopic expression of large amount of E2F-1 expression vector.
Positive_regulation (up-regulation) of TSP-1 promoter
4) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0.07 Pain Relevance 0
In order to define the response elements in TSP1 promoter for E2F-1 up-regulation, initially, we did fine mapping for TSP1 promoter.
Positive_regulation (up-regulation) of TSP1
5) Confidence 0.43 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2955548 Disease Relevance 0 Pain Relevance 0
Angiogenesis is under the control of numerous inducers, including the vascular endothelial growth factor (VEGF) family and inhibitors, such as thrombospondin-1 (TSP-1) [9]
Positive_regulation (inducers) of TSP-1
6) Confidence 0.40 Published 2009 Journal J Ovarian Res Section Body Doc Link PMC2785805 Disease Relevance 1.46 Pain Relevance 0.86
We conclude that although thrombospondin-1 seems to play a key role in the local development of endometriotic lesions, the disease is not associated with a significant modulation in the levels of circulating thrombospondin-1 and the activity of endometriosis can not be monitored using serum levels.
Positive_regulation (circulating) of thrombospondin-1 associated with endometriosis and disease
7) Confidence 0.40 Published 2009 Journal J Ovarian Res Section Body Doc Link PMC2785805 Disease Relevance 1.16 Pain Relevance 0.40
Metronomic low-dose chemotherapy with either trofosfamide or capecitabine may enhance the important antiangiogenic factor thrombospondin-1 in serum with simultaneously negligible cytotoxic activity of the respective drugs [20].
Spec (may) Positive_regulation (enhance) of thrombospondin-1
8) Confidence 0.10 Published 2008 Journal Cancer Microenviron Section Body Doc Link PMC2654356 Disease Relevance 1.08 Pain Relevance 0.42
The significance of increased TSP1 mRNA during labor may relate to homeostasis and merits further study.
Positive_regulation (increased) of TSP1
9) Confidence 0.04 Published 2001 Journal J. Endocrinol. Section Abstract Doc Link 11739010 Disease Relevance 0 Pain Relevance 0.10
Suppression of PTTG1 with siRNA a 2-fold induction of TSP-1 was observed.
Positive_regulation (induction) of TSP-1
10) Confidence 0.04 Published 2008 Journal J Ovarian Res Section Body Doc Link PMC2584053 Disease Relevance 0.20 Pain Relevance 0
Such effects may be secondary to induction of an endogenous inhibitor of angiogenesis, thrombospondin-1, induced by low-dose chemotherapy by as yet unknown mechanisms, rather than direct inhibition of endothelial cell growth, or survival [9].
Positive_regulation (induced) of thrombospondin-1 in endothelial cell
11) Confidence 0.03 Published 2007 Journal BMC Cancer Section Body Doc Link PMC1863429 Disease Relevance 0.54 Pain Relevance 0
TSP1 mRNA increased significantly in both the fundus and lower uterine segment during labor.
Positive_regulation (increased) of TSP1 in fundus
12) Confidence 0.03 Published 2001 Journal J. Endocrinol. Section Abstract Doc Link 11739010 Disease Relevance 0 Pain Relevance 0.06

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox